Gene

ABL1

ABL proto-oncogene 1, non-receptor tyrosine kinase

Explore in graph →CI-GENE-00000153HGNC:76 ENSG00000097007 NCBI 25 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (617)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 51–100 of 617 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABL1 M237V1
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Sensitivity Response	—

Cohorts

Alteration frequency by cohort (122)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved122 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Cutaneous Squamous Cell Carcinoma (DFCI, Clin Cancer Res 2015) cscc_dfarber_2015	Skin Squamous Cell Carcinoma	Ssm

Literature

Linked publications (65)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 65 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
· Oncogene · 2002 · PMID 12476305 · validated civic_curation pubmed
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
· Leuk Res · 2010 · PMID 20537386 · validated civic_curation pubmed
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
· N Engl J Med · 2014 · PMID 25207766 · validated civic_curation pubmed
Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
· Oncotarget · 2017 · PMID 27894077 · validated civic_curation pubmed

ABL1 M388L1
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Sensitivity Response	—	submitted	EID4707 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic

ABL1 M388L1

Dasatinib

Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS

Predictive

Supports Sensitivity Response

—

submitted

EID4707

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

ABL1 Non-P-Loop Mutation2
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	B	Does Not Support Resistance	3	accepted	EID6337 In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysi… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	B	Does Not Support Resistance	3	accepted	EID6998 This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC	civic

ABL1 R351W2
Dasatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	accepted	EID4787 In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to dasatinib. This line showed a significant reduction in colony fo… (full text at CIViC) PMID 26758680 · Testoni et al., 2016 · Open in CIViC	civic
Imatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	5	accepted	EID6376 In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to imatinib. This line showed a significant reduction in colony for… (full text at CIViC) PMID 26758680 · Testoni et al., 2016 · Open in CIViC	civic

ABL1 T315I4
Asciminib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	A	Supports Sensitivity Response	4	submitted	EID11225 In phase 1, dose-escalation trial 141 patients with chronic-phase chronic myeloid leukemia (CML) and 9 patients with accelerated-phase CML who had previously taken at least two ATP-competitive tyrosin… (full text at CIViC) PMID 31826340 · Hughes et al., 2019 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	rejected	EID6284 In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	3	rejected	EID6195 In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic
Ponatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	A	Supports Sensitivity Response	4	submitted	EID11226 In a phase 2, dose-reduction trial, 282 patients were enrolled who had previously been treated with at least 2 prior TKIs or had a T315I mutation. Efficacy was assessed on an interim analysis based on… (full text at CIViC) PMID 34407543 · Cortes et al., 2021 · Open in CIViC	civic

ABL1 Fusion7
(diagnostic)	Acute Lymphoblastic Leukemia	Diagnostic	B	Supports Positive	3	rejected	EID9156 SFPQ-ABL1fusion was identified in Ph-like ALL PMID 31935290 · Harvey et al., 2020 · Open in CIViC	civic
(prognostic)	Acute Lymphoblastic Leukemia	Prognostic	B	Supports Poor Outcome	3	rejected	EID9157 patients with Ph-like ALL had an inferior 5-year event-free survival compared with patients with non–Ph-like ALL (22.5% [95% CI, 14.9% to 29.3%; n = 155] v 49.3% [95% CI, 42.8% to 56.2%; n = 247], res… (full text at CIViC) PMID 27870571 · Roberts et al., 2017 · Open in CIViC	civic
(oncogenic)	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Oncogenic	C	Supports Oncogenicity	3	accepted	EID9158 The authors describe two cases of B-lymphoblastic leukemia (B-ALL) with the t(1;9)(p34;q34) rearrangement, resulting in a fusion between the pre-mRNA processing protein gene SFPQ and the ABL1 kinase g… (full text at CIViC) PMID 21388681 · Duhoux et al., 2011 · Open in CIViC	civic
(diagnostic)	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Diagnostic	C	Supports Positive	3	accepted	EID9160 A 34-year-old woman was hospitalized because of weakness and mild fever. Physical examination revealed multiple and superficial lymph nodes. Peripheral blood counting showed a 47% blasts. Bone marrow … (full text at CIViC) PMID 27894117 · Sheng et al., 2017 · Open in CIViC	civic
(oncogenic)	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Oncogenic	C	Supports Oncogenicity	2	accepted	EID9161 A 22-year-old male presenting with B-lymphoblastic leukemia (B-ALL) characterized by a t(1;9)(p34;q34) was found to carry an SFPQ-ABL1 fusion. The fusion was confirmed by amplification of the genomic … (full text at CIViC) PMID 18205209 · Hidalgo-Curtis et al., 2008 · Open in CIViC	civic
〃	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Oncogenic	C	Supports Oncogenicity	2	accepted	EID9362 219 newly diagnosed NCI high-risk, Ph-negative, B-ALL patients between ages 1 to 18 were enrolled on DFCI ALL Consortium protocol 05-001 (NCT00400946) between 2005 and 2011. This study sought to deter… (full text at CIViC) PMID 29507076 · Tran et al., 2018 · Open in CIViC	civic
Dasatinib + ImatinibSequential	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID9159 Using fluorescence in situ hybridization (FISH) analysis with break-apart probes, the authors screened retrospectively 55 pediatric and 50 adult B-lymphoblastic leukemia (B-ALL) cases negative for com… (full text at CIViC) PMID 32306475 · Biloglav et al., 2020 · Open in CIViC	civic